Hansa Biopharma AB · OMXSTO:HNSA
Hansa Biopharma AB — Q3 2026 Earnings Presentation
40 slides from Hansa Biopharma AB's earnings presentation, Nov 11, 2026
Slide 1: January-September Interim Report Conference Call
® January-September Interim Report Conference Call 11th of November 2026
Slide 2: Forward-looking statements
Forward-looking statements ® This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Q3 2026 Conference Call: Agenda
Q3 2026 Conference Call: Agenda ® 11th of November, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Clinical Update Richard Philipson Chief Medical Officer Financial Results Adam Cutler Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 20
Slide 4: Key Achievements in Q3 2026
® Key Achievements in Q3 2026 Business Overview Pipeline & Regulatory Update Closing of SERB out-licensing transaction on July 1: Resources focused on transition activities, transfer of MAH and EMA submission. Recognition of PAES / ConfIdes data: Oral presentation of topline PAES data at ASN as well
Slide 5: Transaction Overview: €115 million licensing agreement for Idefirix
Transaction Overview: ® €115 million licensing agreement for Idefirix Transaction Scope Partnership Responsibilities Exclusive out-licensing of Idefirix for transplantation in EU, SERB Pharmaceuticals Hansa Biopharma UK, Switzerland, Norway, Liechtenstein, Iceland and Middle East and North Africa (M
Slide 6: Q3 2026 Conference Call: Agenda
Q3 2026 Conference Call: Agenda ® 11th of November, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Clinical Update Richard Philipson Chief Medical Officer Financial Results Adam Cutler Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 20
Slide 7: US kidney transplant: a growing market with high unmet needs
US kidney transplant: a growing market with high unmet needs ® Significant unmet medical need with thousands of highly sensitized patients waiting for a transplant US kidney transplant waitlist is growing ~27,000 ~560,000 on dialysis in the US transplanted/year with 80% being deceased donor organs ~
Slide 8: Concentrated US market with 200 transplant centers
Concentrated US market with 200 transplant centers; ConfIdeS ® centers representing 25% of annual kidney transplant volume Northwestern U Wash Mayo Rochester U of Minnesota MC Wisconsin Mass General NYU Langone Columbia Cedars Sinai Cornell USC UCSF Mayo AZ U Penn CPMC Johns Hopkins Banner Phoenix S
Slide 9: Critical pre-launch activities accomplished
Critical pre-launch activities accomplished ® 1 2 3 HCP and patient engagement Market access and distribution Recruitment of US team • Presented ConfIdeS at TTS and ASHI • NTAP application submitted in • Hired Head of US Sales: 27 years of • European phase III PAES data October 2026 experience, laun
Slide 10: Key value driver: Securing broad market access
® Key value driver: Securing broad market access ESRD patients are eligible, but must apply Medicare • DRG and outlier payments Patient can visit any Medicare center FFS • NTAP if approved Hospitals’ CCR will impact transplant economics Commercially managed plans contracted with Medicare Medicare •
Slide 11: Pre-launch efforts: focus on clinical and operational center readiness
Pre-launch efforts: focus on clinical and operational center readiness ® Clinical readiness Operational and financial readiness Field medical team engaging with top ~100 centers Field market access team engaging with the same top ~100 representing 80% of US kidney transplant volume centers as th
Slide 12: Imlifidase has the potential to change the treatment paradigm
® Imlifidase has the potential to change the treatment paradigm* Addresses one of the most challenging unmet needs in kidney transplantation • Thousands of highly sensitized patients remain unable to access a compatible donor despite years on the waitlist Enables transplantation where it was previou
Slide 13: Q3 2026 Conference Call: Agenda
® Q3 2026 Conference Call: Agenda 11th of November, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Clinical Update Richard Philipson Chief Medical Officer Financial Results Adam Cutler Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 20
Slide 14: Encore Presentation: The ConfIdeS Study
® Encore Presentation: The ConfIdeS Study: Imlifidase desensitization results in timelier transplant with superior 1-year eGFR among highly sensitized patients compared to control 31st International Congress of the Transplantation Society September 20 – 23 Sydney, Australia © 2026, Hansa Biopharma A
Slide 15: ConfIdeS Trial Design
ConfIdeS Trial Design ® Randomized controlled trial in highly sensitized patient population with a cPRA value ≥99.90% Organ Randomization 12 months offer (n=64) Imlifidase Pre-screening Screening n=32 Delisting of Eligibility unacceptable assessment antigen(s) Control n=32 Accept Imlifidase treatmen
Slide 16: Time to Transplantation
Time to Transplantation ® Imlifidase (n=32) Control (n=32) Transplanted with the randomization organ offer 84% (n=27) 9% (n=3) Mean time to transplantation 1.9 days 96.2 days Mean time to randomization* 116 days 135 days Mean time on dialysis 2,665 days 1,898 days Transplanted during the course of t
Slide 17: Primary Endpoint – eGFR at 12 Months
Primary Endpoint – eGFR at 12 Months ® Imlifidase (N=32) Control (N=32) 90 eGFR, MDRD (mL/min/1.73 m2) 80 70 51.5 60 50 mL/min/1.73m2 40 30 20 19.3 mL/min/1.73m2 10 0 0 30 100 200 300 366 Days from randomization eGFR was 51.5 mL/min/1.73 m2 in imlifidase arm compared with 19.3 mL/min/1.73 m2 in the
Slide 18: Dialysis Dependency & CKD at 12 Months
Dialysis Dependency & CKD at 12 Months ® DIALYSIS DEPENDENCY AT 12 MONTHS 5 18 Dialysis dependency was lower in the imlifidase arm (5 patients) than in the control arm patients vs patients (17 patients) (p=0.0007) Imlifidase Control CKD stage at 12 months for transplanted patients eGFR Imlifidase (n
Slide 19: AMR Status & Effect on eGFR at 12 Months
AMR Status & Effect on eGFR at 12 Months ® Treatment Arm – AMR status AMR OCCURRENCE Imlifidase – Yes (N=16) Control – Yes (N=6) 46% Imlifidase – No (N=12) Control – No (N=9) 57% 60 16/28 patients 6/13 patients eGFR, MDRD (mL/min/1.73 Imlifidase Control 45 m2) 30 No grafts in the imlifidase arm were
Slide 20: Patient Survival & Adverse Events
Patient Survival & Adverse Events ® Patient survival Safety profile Imlifidase (n=32) Control (n=32) AEs and SAEs reflect post-transplant complications per current immunosuppressive practice and are consistent with previous 97% 100% clinical trial experience No imlifidase infusion was discontinued d
Slide 21: Post-Authorization Efficacy and Safety (PAES) Trial
® Post-Authorization Efficacy and Safety (PAES): An Open-Label Post- Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe American Society of Nephrology Kidney Week October 21 – 25 Denver, USA © 2026, Hansa Biopharma AB 21
Slide 22: Trial Design
Trial Design ® Imlifidase cohort Pre-screening Screening Imlifidase Tx Positive Crossmatch Crossmatch Conversion Organ Inclusion offer 12 Delisting of unacceptable antigen(s) months Non-comparative concurrent reference cohort Screening-Tx 12 months Non-comparative historical reference cohort (CTS EU
Slide 23: Patient Eligibility
Patient Eligibility ® Imlifidase cohort Concurrent cohort Historical cohort (CTS*) Male or female patient aged 18-75 years with ABO-compatible DD aged 10-70 years Highly sensitized Sensitized Not sensitized (cPRA ≥ 95%) (cPRA ≥ 50%) Crossmatch positive to donor Crossmatch negative to Crossmatch nega
Slide 24: Baseline Characteristics
Baseline Characteristics ® Imlifidase Cohort Concurrent Cohort (N=50) (N=63) Age in years (mean, SD) 50.1 (9.62) 55.6 (11.32) Female, n (%) 20 (40.0) 26 (41.3) Pregnancy, n (% of female) 12 (60.0) 21 (80.8) On dialysis at time of transplant, n (%) 50 (100) 56 (88.9) Median time on dialysis prior to
Slide 25: Main Outcomes
Main Outcomes ® Imlifidase Concurrent Historical (N=50) Cohort (N=63) Cohort (N=100) Primary: Graft failure-free survival, no. events 5 5 10 Kaplan-Meier survival estimate at one year 90.0% 92.0% 90% Secondary: Patient survival, no. events 1 2 2 Kaplan-Meier survival estimate at one year 98.0% 96.8%
Slide 26: Graft Function Over Time: eGFR and Proteinuria
Graft Function Over Time: eGFR and Proteinuria ® eGFR from Day 1 to 365 Proteinuria from Day 1 to 365 Imlifidase Imlifidase 90 70 75 60 60 50 eGFR, MDRD (mL/min/1.73 m2) 40 Protein/Creatinine (mg/mmol) 45 30 30 20 15 10 0 0 1 3 9 180 240 300 365 0 0 30 90 180 240 300 365 Concurrent Concurrent 90 70
Slide 27: AMR and Kidney Function (Imlifidase Cohort)
AMR and Kidney Function ® (Imlifidase Cohort) K-M curve AMR risk estimates eGFR in patients with and without AMR 1.0 120 eGFR, MDRD (mL/min/1.73 m2) 0.9 105 AMR 0.8 90 0.7 No 0.6 75 AMR risk Yes 0.5 60 0.4 45 0.3 0.2 30 0.1 15 0.0 0 1 30 90 180 240 300 365 1 30 90 180 240 300 365 Trial Day At Risk 5
Slide 28: Safety
Safety ® Treatment-emergent Adverse Event (TEAE) Imlifidase Imlifidase • Imlifidase was well tolerated, [within 30 days after enrolment] (N=51) (N=51) patient survival was 98% Any serious TEAE 28 (54.9) Treatment-related serious TEAE 0 • Imlifidase had a safety profile Leading to death 0 Leading to
Slide 29: HNSA-5487 in Guillain-Barré Syndrome
® HNSA-5487 in Guillain-Barré Syndrome © 2026, Hansa Biopharma AB 29
Slide 30: HNSA-5487 in Guillain-Barré Syndrome
® HNSA-5487 in Guillain-Barré Syndrome • HNSA-5487 is a novel IgG-cleaving enzyme generated from our in-house platform, in development for the treatment of Guillain-Barré syndrome (GBS) • Following submission of a comprehensive pre-IND briefing package in Q1 2026, feedback was received from FDA in Q
Slide 31: Q3 2026 Conference Call: Agenda
® Q3 2026 Conference Call: Agenda 11th of November, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Clinical Update Richard Philipson Chief Medical Officer Financial Results Adam Cutler Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 20
Slide 32: Q3 2026 Revenue
® Q3 2026 Revenue Total Revenue 143.0 MSEK 3Q 2026 revenue consisted of: • License revenue under the SERB agreement of 121.6 MSEK (part of the €110 million upfront payment received in July and recognized on a straight-line basis through December 2028). • Supply and service revenue from SERB of 20.8
Slide 33: Continued Investments in R&D & Commercialization
® Continued Investments in R&D & Commercialization SG&A Expenses R&D Expenses Operating Loss Q3 2026 Q3 2026 Q3 2026 -1481 MSEK -65 MSEK -139 MSEK Year-over-year Year-over-year Year-over-year ▲ 67%1 ▼ 7% ▼ 6% vs Q3’25 -88 MSEK vs Q3’25 -70 MSEK vs Q3’25 -148 MSEK 1Q3'26 SG&A included costs associate
Slide 34: Summary of Cash & Headcount
® Summary of Cash & Headcount Operating Cash Flow Cash & Equivalents Employees Q3 2026 Q3 2026 Q3 2026 964 MSEK 1,337 MSEK 111 FTEs Year-over-year Year-over-year vs Q3'25: -107 MSEK ▲ 430% ▼ 17% vs Q3'25: 252 MSEK vs Q3’25: 133 FTEs Operating Cash Flow & Cash in MSEK; Employees in full-time equivale
Slide 35: Q3 2026 Conference Call: Agenda
Q3 2026 Conference Call: Agenda ® 11th of November, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Clinical Update Richard Philipson Chief Medical Officer Financial Results Adam Cutler Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 20
Slide 36: Summary
Summary ® Strong foundation and clear roadmap Robust financial position Value inflection point in Q4 Execution focus Experienced team © 2026, Hansa Biopharma AB 36
Slide 37: Experienced and Proven Leadership Team
Experienced and Proven Leadership Team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén Chief Executive Officer Chief Operating Officer, President US 20+ yrs rare disease leader and former investor, Succes
Slide 38: Q&A
® Q&A © 2026, Hansa Biopharma AB 38
Slide 39: Hansa Biopharma contacts and key events
® Hansa Biopharma contacts and key events Contacts Upcoming Events 2026 Adam Cutler NOV 12 Stifel 2026 Healthcare Conference Chief Financial Officer Email: ir@hansabiopharma.com NOV 16-21 Jefferies Global Healthcare Conference in London NOV 24 Aktiespararna in Stockholm NOV 24 SEB Conference, Stockh
Slide 40: HAN Sar
IZ HAN Sar BIOPHARMA